Juan Luis Steegmann Hospital de la Princesa. Madrid. JL Steegmann
|
|
- Joleen Wiggins
- 6 years ago
- Views:
Transcription
1 Juan Luis Steegmann Hospital de la Princesa. Madrid.
2 Juan Luis Steegmann Hospital de la Princesa. Madrid
3 No rush,at least in Chronic Phase Blast Phase*: SCT asap, after restablishing CP with TKI Accelerated phase* Near Blast Phase, or AP developing during TKI As Blast Phase Less advanced accelerated phase at diagnosis: Treat as first chronic phase First chronic: Let s see, give me ten minutes * Taken form Pavlu J, Szydlo RM, Goldman JM, Apperley JF. Blood 2011;117:
4 Rational BMT mortality and morbidity Good results with 2GTKI in second line Better knowledge of prognostic factors Tailoring 2nd line therapy Bridging the gap with third line Better results with 2GTKI, 1st line Minimizing the need
5 In BMT done in the last decade in one of the most experienced institutions, roughly 15% of the patients died during the first year after SCT Pavlu J, Szydlo RM, Goldman JM, Apperley JF. Blood 2011;117:
6 BMT mortality is at least 25% in the first year if Gratwohl score is 2 or more SCORE OS RFS TRM REL Gratwohl, A., et al. Lancet, (9134): p
7 And the problem is that most patients treated in 2nd line with 2G TKI have scores greater than 2 Sibling: 0; Unrelated: 1 Phase CP: 0 Patient s age: y: 1 > 40 y: 2 Sex match: Female D, Male R: 1 Time Diagnosis BMT > 1 year : 1 Gratwohl, A., et al. Lancet, (9134): p
8 Besides, revised score developed in the last decade did show that most patients considered here will have a substantial mortality Mortality during the first year: Score 2: 20% ; score 3: 35% Revised EBMT score Age, years: <30 (0); (1); >40 (2) Donor: sibling (0); unrelated (2) Interval diagnosis SCT: <1 year (0); >1 year (1) Sex match: female male (1); all other (0) Passweg JR, et al. BrJ Haematol 2004;125:
9 Even more, non myeloablative SCT are associated with good probability of survival, but substantial risk of GVHD Probability of acute GVHD III IV in the first 3 m: 30% Or, R., et al., Blood, (2): p
10 Non myeloablative SCT s s are associated with substantial risk of chronic GVHD Probability of chronic GVHD first 18 m: 55 % Or, R., et al., Blood, (2): p
11 And RIC was not better in terms of TRM, although DFS was slightly better. Still, mortality in the first year is circa 30% in the year group Warlick E, et al Blood 2012;119:
12 TKI ( Dasatinib, Nilotinib, Bosutinib ) have good results in second line Complete cytogenetic responses: 44% 70% Major molecular responses: 22% 50% Overall survival: 70% Event free survival 50 % Hochhaus A et al EHA 2009 #1091 Shah NP et al ASCO 2010 # 6512 ; Shah NP et al ASCO 2011 # 6512 Rea et al EHA 2012 Kantarjian, H. M., F. J. Giles, et al. (2011). Blood 117(4): Khoury HJ ( 2012), Blood 119 : ,
13 Dasatinib as salvage therapy: 6 year follow follow up: The probability of survival is more than 70% MMR 6years : 40% ( R ) ; 49% ( I ) OS 6years : 68% ( R ) ; 78% ( I ) EFS 6years : 46% ( R ) ; 58% ( I ) Rea al, EHA 2012
14 Dasatinib as salvage therapy: The mortality during the first year is less than 5% Rea al, EHA 2012
15 SELECTING THE APPROPRIATE SETTING
16 2nd line therapy after imatinib can be optimized: Cytogenetic response could be better if: Low Risk Group Previous response to Imatinib No ACA s Ph+ No grade III IV neutropenia* Certain baseline cytogenetic response Shorter time between Failure/intolerance and the start of 2ndG TKI No Resistant mutation 1. Milojkovic D, et al. Haematologica 2010;95 (2): Jabbour, E., H. Kantarjian, et al. (2010). Blood: blood Steegmann JL et al. Haematologica. EHA Manuscript, submitted
17 Predicting Responses to Second Line TKI: Hammersmith Score Cytogenetic response to imatinib (CCyR, 0; 1 94% Ph+, 1; > 95% Ph+, 3) Sokal score (Low risk, 0; int+high, 0.5) Neutropenia 3 4 leading to Im reduction(no, 0; yes, 1) p< Good risk n=20 100% Score < <2.5 >2.5 Risk good intermediate poor Cumulative incidence of CCyR p< p=0.001 Intermediate risk n=26 Poor risk n=34 21% Prob CCyR Months from starting 2G TKI Therapy Milojkovic, D. et al. Haematologica 2010;95:
18 Prognosis with 2 nd line TKIs in CML: MDACC score Adverse factors: Performance Status 1 and lack of CyR to imatinib Jabbour E. et al. Blood Feb 10;117(6):
19 Predicting survival with cytogenetics Model No CyR to Im MDACC EFS ECOG >0 MDACC EFS, OS Displaced all in the multivariate analysis for OS : HR: 2,4: No CyR at 3 m Hammersmith EFS, PFS, OS No PCyR at 6 m Hammersmith EFS, PFS, OS CA EFS* No CCyR at 12 m Hammersmith EFS, OS CA EFS* No MCyR at 12 m MDACC Displaced all in the multivariate analysis for EFS : HR: 2,3 1. Milojkovic D, et al. Haematologica 2010;95 (2): Jabbour, E., H. Kantarjian, et al. (2010). Blood: blood Saglio, EHA 2011
20 Predicting survival with molecular response 3M: 1 10% VS >10% STUDY Hammersmith 1 EFS: 49% v 13% PFS: 91% v 68% OS: 91% v 72% 3M: 1 10% VS >10% CA EFS: 64% V 26% OS: 85% V 65% 3M: <1% V1 10% VS >10% 6M: 1% VS >1% CAMN PFS: 85% v 67% v 42% OS: 95% v 81% V 71% Hammersmith 1 EFS: 58% v 18% PFS: 91% v 74% OS: 91% v 77% 6M: CA No data 1. Milojkovic, Blood Rea et al EHA Giles et al submitted 6M: <1% V1 10% VS >10% 12 M MMR vs CCyR, No MMR CAMN PFS: 86% v 58% v 39% OS: 95% v 82% V 73% CAMN PFS: 97% v 96%
21 Response to 2 nd generation TKI in 2 nd line therapy ELN 09 recommendations Baseline Suboptimal Failure Warning 3 months 36 65% Ph+ No CyR Strong New Mutation* 6 months 1 35% Ph % Ph+ Strong New Mutation* 12 months No MMR >35% Ph+ Strong New Mutation* No HR to imatinib Strong mutation* Clonal evolution 66% 95% Ph % Ph+ *Mutation poorly sensitive to tyrosine kinase inhibitors. HR=hematologic response. Baccarani M, et al. J Clin Oncol 2009; 27 (35):
22 Response to 2 nd generation TKI in 2 nd line therapy ELN 2013 recommendations Baseline Optimal Failure Warning 3 months NO CHR Ph + > 95% or BCR ABL > 10% NEW MUTATIONS 6 months Ph + > 35% or BCR ABL > 10% NEW MUTATIONS 12 months Ph + > 35% or BCR ABL > 1% Any time LOSS OF CHR LOSS OF CCgR or PCgR NEW MUTATIONS CONFIRMED LOSS OF MMR
23 A practical example, taking the results from CA ( dasatinib 2nd line): OS by 6 years: 83% if MR1 at 3 m Shah et al 6 year follow up of CA ASCO 2012
24 A practical example, taking the results from CA ( dasatinib 2nd line): OS by 6 years: > 83% if PCyR or better at 6 m Shah et al 5 year follow up of CA ASCO 2011
25 A practical example, taking the results from CA ( dasatinib 2nd line): OS by 6 years: > 88 % if PCyR or better at 12 m Shah et al 5 year follow up of CA ASCO 2011
26 Third line therapy in CP, resistant CCyR could be obtained in 42% of the patients n CHR MCyR CCyR Im D N 1, % 22% 43% 24% 33% Im D B % 14% Im N D % 13% Im N B % 27% Im 2G TKI 26 50% 35% Im 2GTKI P* 74 53%** 42%** Garg et al., Blood Nov 12;114(20): Giles et al., Leukemia Jul;24(7): Khoury, H.J., et al.,. Blood, (15): p Gambacorti Passerini et al., Blood (ASH Annual Meeting Abstracts) : Abstract 3434 Ibrahim, A.R., et al.,. Blood, (25): p Cortes, J. et al,eha All group: 79% Resistant ** T315I: 77%, 74% MCyR if prior mutation 2,4 : Nilo as third TKI: 25% Bosu as third TKI: 29% MCyR median duration Nilo as third TKI: 18 months Dasa as third TKI: 16 months ( CCyR) Bosu after Dasa: 4,5 months Bosu after Nilo: NR at 48 m Pona: FU too short: Est. 12m: 92%
27 With the results of 2G TKI, first line, only a tiny minority did not obtain the 10% threshold at 3 m
28 A practical example, taking the results from ENESTnd ( Nilotinib 1st line): PFS by 3 years: More than 95 % if MR1 at 3 m Hochhaus A, et al. Haematologica. 2012;97(s1):237 [abstract 0584].
29 Conclusions. In a patient with CML in CP BMT could be a good 3rd line therapy. Do not rush to use it in second line. Detect warning signs before 2nd line TKI treatment. BMT is a good option if failure to 2 nd line, and the EBMT score is 0 3. BMT could be considered in patients not having an optimal response to 2 nd line. Hematologic resistance to Imatinib, Mutations, High Hammersmith or MDACC score Providing EBMT score is 0 2.
30 THANK YOU GRACIAS
Role of Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed CML. GIUSEPPE SAGLIO, MD University of Torino, Italy
Role of Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed CML GIUSEPPE SAGLIO, MD University of Torino, Italy Outcome in 282 Patients Treated with Imatinib First Line in Hammersmith Hospital
More informationAllogeneic SCT for. 1st TKI. Vienna Austria. Dr. Eduardo Olavarría Complejo Hospitalario de Navarra
The International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) Berlin, Germany September 8-11, 2011 Vienna Austria Allogeneic SCT for CML Allogeneic after failure
More informationELN Recommendations on treatment choice and response. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
ELN Recommendations on treatment choice and response Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy ELN 2013 Response to Front-line Treatment Baseline 3 months 6 months OPTIMAL
More informationEUROPEAN LEUKEMIANET RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
EUROPEAN LEUKEMIANET RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA SAN DIEGO, 11 DECEMBER 2011 AMSTERDAM, 14 JUNE 2012 BALTIMORE, 20 SEPTEMBER 2012 ATLANTA, 6 DECEMBER 2012 ELN, CML Panel Jane Apperley
More informationGuidelines and real World: Management of CML in chronic and advanced phases. Carolina Pavlovsky. FUNDALEU May 2017 Frankfurt
Guidelines and real World: Management of CML in chronic and advanced phases Carolina Pavlovsky. FUNDALEU 26-28 May 217 Frankfurt Some Issues in CML 217 First Line treatment: Imatinib vs 2nd generation
More informationIRIS 8-Year Update. Management of TKI Resistance Will KD mutations matter? Sustained CCyR on study. 37% Unacceptable Outcome 17% 53% 15%
Management of TKI Resistance Will KD mutations matter? IRIS 8-Year Update 17% 53% 5% 15% 37% Unacceptable Outcome No CCyR Lost CCyR CCyR Other 3% 7% Safety Lost-regained CCyR Sustained CCyR on study Deininger
More informationHOW I TREAT CML. 4. KONGRES HEMATOLOGOV IN TRANSFUZIOLOGOV SLOVENIJE Z MEDNARODNO UDELEŽBO Terme Olimia, Podčetrtek,
HOW I TREAT CML 4. KONGRES HEMATOLOGOV IN TRANSFUZIOLOGOV SLOVENIJE Z MEDNARODNO UDELEŽBO Terme Olimia, Podčetrtek, 12. - 14. april, 2012 Gianantonio Rosti Dpt of Hematology and Oncological Sciences S.
More informationWhat is the optimal management strategy for younger CP-CML patients with matched, related donors who fail to achieve CCyR
What is the optimal management strategy for younger CP-CML patients with matched, related donors who fail to achieve CCyR after 18 months of imatinib? Second generation TKIs as a bridge to allogeneic SCT
More informationHSCT for Myeloproliferative Disorders. Jane Apperley
HSCT for Myeloproliferative Disorders Jane Apperley Myeloproliferative disorders CML Polycythemia vera Essential thrombocythemia Primary myelofibrosis bcr-abl + bcr-abl - JAK2 (valine to phenylalanin an
More information2 nd Generation TKI Frontline Therapy in CML
2 nd Generation TKI Frontline Therapy in CML Elias Jabbour, M.D. April 212 New York Frontline Therapy of CML in 212 - imatinib 4 mg daily - nilotinib 3 mg BID - dasatinib 1 mg daily Second / third line
More informationContemporary and Future Approaches in CML. Emory Meeting; Sea Island August 2014 Hagop Kantarjian, M.D.
Contemporary and Future Approaches in CML Emory Meeting; Sea Island August 2014 Hagop Kantarjian, M.D. 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course Fatal Indolent Prognosis
More informationCML: Living with a Chronic Disease
CML: Living with a Chronic Disease Jorge Cortes, MD Chief, CML and AML Sections Department of Leukemia M. D. Anderson Cancer Center Houston, Texas Survival in Early Chronic Phase CML TKI Interferon Chemotherapy
More information2nd generation TKIs to first line therapy
New Horizons 2011 Newly diagnosed CML moving 2nd generation TKIs to first line therapy Gianantonio Rosti Dept. Of Hematology and Oncology St. Orsola-Malpighi University Hospital Bologna (Italy) GIMEMA
More informationChronic Myeloid Leukaemia
Chronic Myeloid Leukaemia Molecular Response: What is really important? Jeff Szer The Royal Melbourne Hospital PROBABILITY, % PROBABILITY OF SURVIVAL AFTER MYELOABLATIVE TRANSPLANTS FOR CML IN CHRONIC
More informationCML and Future Perspective. Hani Al-Hashmi, MD
CML and Future Perspective Hani Al-Hashmi, MD Objectives Learning from CML history Outcome of interest to clinician Patient and community interest!! Learning from CML history Survival Probability (All
More informationBMS Satellite Symposium
ICKSH 2018 BMS Satellite Symposium Emerging Trends in CML Management CHAIRMAN The Head of Catholic Hematology Hospital The Director of the Catholic Leukemia Research Institute at the Catholic University
More informationManagement of CML in blast crisis. Lymphoma Tumor Board November 27, 2015
Management of CML in blast crisis Lymphoma Tumor Board November 27, 2015 Chronic Phase CML - 2. Peter Maslak, ASH Image Bank 2011; 2011-2455 Copyright 2011 American Society of Hematology. Copyright restrictions
More informationBlast Phase Chronic Myelogenous Leukemia
Blast Phase Chronic Myelogenous Leukemia Benjamin Powers, MD; and Suman Kambhampati, MD The dramatic improvement in survival with tyrosine kinase inhibitors has not been demonstrated in the advanced blast
More informationCML David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML Current treatment options for CML
1 CML 2012 LLS Jan 26, 2012 David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML 2012 Current treatment options for CML patients Emerging therapies for CML treatment
More informationContemporary and Future Approaches in Management of CML. Disclosures
Winship Cancer Institute of Emory University Contemporary and Future Approaches in Management of CML Hagop Kantarjian, MD Chairman and Professor, Department of Leukemia University of Texas M. D. Anderson
More informationNEW DRUGS IN HEMATOLOGY
NEW DRUGS IN HEMATOLOGY BOLOGNA, 15-17 April 2013 TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA MICHELE BACCARANI michele.baccarani@unibo.it Historic Development of CML Therapy Palliative Therapy
More informationHistory of CML Treatment
History of CML Treatment Eduardo Olavarria No conflict of interest Lisbon, 20th March 2018 #EBMT18 www.ebmt.or What is CML? The mystery of chronic myeloid leukaemia Chronic myeloid leukaemia Often diagnosed
More informationSESSION III: Chronic myeloid leukemia PONATINIB. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
SESSION III: Chronic myeloid leukemia PONATINIB Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy Ponatinib A Pan-BCR-ABL Inhibitor Rationally designed inhibitor of BCR- ABL
More informationHow I treat high risck CML
Torino, September 14, 2018 How I treat high risck CML Patrizia Pregno Hematology Dept. Citta della Salute e della Scienza Torino Disclosures Advisory Board: Novartis, Pfizer, Incyte Speaker Honoraria:
More informationCML: Yesterday, Today and Tomorrow. Jorge Cortes, MD Chief CML Section Department of Leukemia The University of Texas, M.D. Anderson Cancer Center
CML: Yesterday, Today and Tomorrow Jorge Cortes, MD Chief CML Section Department of Leukemia The University of Texas, M.D. Anderson Cancer Center Five Years of Signal Transduction Inhibition The Beginning
More informationWhat is New in CML in Hagop Kantarjian, M.D. February 2011
What is New in CML in 2011 Hagop Kantarjian, M.D. February 2011 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course Fatal Indolent Prognosis Poor Excellent 10-yr survival 10% 84-90%
More informationChronic Myeloid Leukemia A Disease of Young at Heart but Not of Body
Chronic Myeloid Leukemia A Disease of Young at Heart but Not of Body Jeffrey H Lipton, PhD MD FRCPC Staff Physician, Princess Margaret Cancer Centre Professor of Medicine University of Toronto POGO November,
More informationNew drugs in first-line therapy
New drugs in first-line therapy Gianantonio Rosti Dept of Hematology and Oncology Seràgnoli, Bologna University (Italy) GIMEMA (Gruppo Italiano Malattie Ematologiche dell Adulto) CML WORKING PARTY IRIS
More informationVenice Meeting Highlights: Key lessons. Conclusions Michele Baccarani Rüdiger Hehlmann
Venice Meeting Highlights: Key lessons Conclusions Michele Baccarani Rüdiger Hehlmann CML therapy in the imatinib era CML prognosis has improved dramatically Cellular and molecular biology studies help
More information10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN OXFORD
10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN OXFORD Dalia Khan 1, Noemi Roy 1, Vasha Bari 1, Grant Vallance 1, Helene Dreau 1, Timothy Littlewood 1, Andrew Peniket 1, Paresh Vyas
More informationA 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable.
1 Case 1 A 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable. CBC and bone marrow aspiration and biopsy were done. Chromosome study showed she had t(9;22)
More informationOxford Style Debate on STOPPING Treatment.
Oxford Style Debate on STOPPING Treatment. This house believes that there are good reasons NOT to stop CML treatment. It should be done within clinical trials, OR only in expert centers where frequent,
More informationMilestones and Monitoring
Curr Hematol Malig Rep (2015) 10:167 172 DOI 10.1007/s11899-015-0258-1 CHRONIC MYELOID LEUKEMIAS (E JABBOUR, SECTION EDITOR) Milestones and Monitoring Alessandro Morotti 1 & Carmen Fava 1 & Giuseppe Saglio
More informationRESEARCH ARTICLE. Introduction. Methods Wiley Periodicals, Inc.
BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase AJH Dennis (Dong Hwan) Kim, 1 * Nada Hamad,
More informationEVI-1 oncogene expression predicts survival in chronic phase CML patients resistant to imatinib
EVI-1 oncogene expression predicts survival in chronic phase CML patients resistant to imatinib Mustafa Daghistani Department of Haematology, Imperial College London at Hammersmith Hospital, Du Cane Road,
More informationThe concept of TFR (Treatment Free Remission) in CML
The concept of TFR (Treatment Free Remission) in CML Giuseppe Saglio University of Turin, Italy What can we expect today on long-term therapy with TKIs in CML? German CML study IV Relative and overall
More informationMolecular monitoring of CML patients
EHA, Education Session, CML Stockholm, 14 June 2013 Molecular monitoring of CML patients Martin C. Müller Medical Faculty Mannheim Ruprecht-Karls-University Heidelberg Mannheim, Germany Disclosures Research
More informationStopping Treatment in CML and dose reduction in clinical practice: Can we do it safely? YES WE CAN!
Stopping Treatment in CML and dose reduction in clinical practice: Can we do it safely? YES WE CAN! Dragana Milojković The Hammersmith Hospital, London, UK Leukemic burden Current Aim of TKI therapy Molecular
More informationThe BCR-ABL1 fusion. Epidemiology. At the center of advances in hematology and molecular medicine
At the center of advances in hematology and molecular medicine Philadelphia chromosome-positive chronic myeloid leukemia Robert E. Richard MD PhD rrichard@uw.edu robert.richard@va.gov Philadelphia chromosome
More informationAbstract and Introduction
Tomado con permiso de www.medscape.com From Cancer Control: Journal of the Moffitt Cancer Center Tyrosine Kinase Inhibitors and Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia:
More informationWhen to change therapy? Andreas Hochhaus Universitätsklinikum Jena, Germany
When to change therapy? Andreas Hochhaus Universitätsklinikum Jena, Germany Chromosome 22 Chromosome 9 e1 1b m-bcr M-bcr e1 e2 b1 b5 5 3 BCR ABL 5 3 1a a2 a3 μ -bcr e19 a11 e1a2 b2a2 b3a2 e19a2 p190 bcr-abl
More informationIS MUTATION ANALYSIS OF BCR-ABL OF ANY VALUE IN CLINICAL MANAGEMENT OF CML PATIENTS? David Marin, Imperial College London
IS MUTATION ANALYSIS OF BCR-ABL OF ANY VALUE IN CLINICAL MANAGEMENT OF CML PATIENTS? David Marin, Imperial College London Tell me generals, are we politicians necessary? I have to admit defeat before starting
More informationLa terapia della LMC: è possibile guarire senza trapianto? Fabrizio Pane
La terapia della LMC: è possibile guarire senza trapianto? Fabrizio Pane What could be the concept of Cure in CML? Sustained DMR with or without TKI therapy And 100% CML-related survival And QoL comparable
More informationAllogeneic Haematopoietic Stem Cell Transplantation for Chronic Myeloid Leukaemia in the Era of Tyrosine Kinase Inhibitors
Allogeneic Haematopoietic Stem Cell Transplantation for Chronic Myeloid Leukaemia in the Era of Tyrosine Kinase Inhibitors Allogeneic haematopoietic stem cell transplant (allosct) is an effective therapeutic
More informationDose reduction. What do we know and how we do it in clinical practice. Andreas Hochhaus
Dose reduction. What do we know and how we do it in clinical practice. Andreas Hochhaus Hadera I Oct 2018 Front-line Randomized Trials in CML-CP Trial Drugs References IRIS IM 400 vs IFN/AraC TOPS IM
More informationCML EHA: what s new? Novità dall EHA >> [ Leucemia mieloide cronica ] Relatore: G. MARTINELLI. Borgo S. Luigi Monteriggioni (Siena) ottobre 2008
Novità dall EHA >> [ Leucemia mieloide cronica ] CML EHA: what s new? Relatore: G. MARTINELLI 27-28 ottobre 2008 Borgo S. Luigi Monteriggioni (Siena) Leucemia mieloide cronica - Copyright FSE 1 CML EHA:
More informationLong-term side effects, comorbidities & their impact on choice of treatment CML management and quality of life. Andreas Hochhaus
Long-term side effects, comorbidities & their impact on choice of treatment CML management and quality of life Andreas Hochhaus Frankfurt I 27.5.2017 sola dosis facit venenum Paracelsus 1493-1541 Swiss
More informationState of the Art Therapy and Monitoring of CML Hagop Kantarjian, M.D. Grand Rounds Hackensack, New Jersey. September 22, 2010
State of the Art Therapy and Monitoring of CML - 2010 Hagop Kantarjian, M.D. Grand Rounds Hackensack, ew Jersey September 22, 2010 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course
More informationCML Update 2016 Arthur 2016
CML Update 2016 Chronic Myeloid Leukemia Splenomegaly CML (3 phase disease) Increased white cells Malignant proliferation of myeloid white cells Initially mature cells a) chronic phase of disease Evolution
More informationState of the Art Therapy and Monitoring of CML Hagop Kantarjian, M.D. Grand Rounds UT Southwestern. October 28, 2010
State of the Art Therapy and Monitoring of CML - 2010 Hagop Kantarjian, M.D. Grand Rounds UT Southwestern October 28, 2010 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course Fatal
More informationSuboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy?
REVIEW IMATINIB TREATMENT FOR CHRONIC MYELOID LEUKEMIA Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy? ELIAS JABBOUR, MD; JORGE E. CORTES,
More informationI nuovi guariti? La malattia minima residua nella leucemia mieloide cronica. Fabrizio Pane
I nuovi guariti? La malattia minima residua nella leucemia mieloide cronica Fabrizio Pane What could be the concept of Cure in CML? Sustained DMR with or without TKI therapy And 100% CML-related survival
More informationMolecular Detection of BCR/ABL1 for the Diagnosis and Monitoring of CML
Molecular Detection of BCR/ABL1 for the Diagnosis and Monitoring of CML Imran Mirza, MD, MS, FRCPC Pathology & Laboratory Medicine Institute Sheikh Khalifa Medical City, Abu Dhabi, UAE. imirza@skmc.ae
More informationNEW DRUGS IN HEMATOLOGY Bologna, 9-11 May 2016 CHRONIC MYELOID LEUKEMIA STATUS OF THE ART OF TREATMENT.
NEW DRUGS IN HEMATOLOGY Bologna, 9-11 May 2016 CHRONIC MYELOID LEUKEMIA STATUS OF THE ART OF TREATMENT Michele.baccarani@unibo.it Michele BACCARANI, MD Professor of Hematology at the Universities of Trieste,
More informationWhat is New in CML Jorge Cortes, MD Chief, CML and AML Sections Department of Leukemia MD Anderson Cancer Center Houston, Texas
What is New in CML 2018 Jorge Cortes, MD Chief, CML and AML Sections Department of Leukemia MD Anderson Cancer Center Houston, Texas Final Results CML-IV Molecular Response with Imatinib 1538 pts newly
More informationLow doses of tyrosine kinase inhibitors in CML
CML Horizons Conference Warsaw 4-6 May 2018 Low doses of tyrosine kinase inhibitors in CML Delphine Rea, MD, PhD Pôle Hématologie Oncologie Radiothérapie INSERM UMR-1160 Centre Hospitalo-Universitaire
More informationResearch Article The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single Institution Experience
Disease Markers Volume 216, Article ID 7531472, 5 pages http://dx.doi.org/1.1155/216/7531472 Research Article The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single
More informationEvaluating Cost-Effectiveness in Later-line Chronic Myeloid Leukemia (CML): Ponatinib in the Third-Line Treatment of CML in Canada
Evaluating Cost-Effectiveness in Later-line Chronic Myeloid Leukemia (CML): Ponatinib in the Third-Line Treatment of CML in Canada Jeffrey H. Lipton, Sergio Iannazzo, Silvia Chiroli, Lisa McGarry 06 CADTH
More informationCurrent Monitoring for CML: Goals and. Jorge Cortes, MD Chief, CML & AML Section Department of Leukemia MD Anderson Cancer Center
Current Monitoring for CML: Goals and Principles Jorge Cortes, MD Chief, CML & AML Section Department of Leukemia MD Anderson Cancer Center Survival in Early Chronic Phase CML MDACC 2009 The Philadelphia
More informationOncology Highlights: Leukemia & Myelodysplastic Syndromes
Oncology Highlights: Leukemia & Myelodysplastic Syndromes Jorge Cortes, MD Department of Leukemia The University of Texas, M.D. Anderson Cancer Center Highlights of the Day Leukemia & MDS AML: The field
More informationAbstract. Research. Keywords: CML, Sokal score, Euro score, EUTOS score. Published: 06/10/2016 Received: 29/05/2016
Prognostic and predictive implications of Sokal, Euro and eutos scores in chronic myeloid leukaemia in the imatinib era experience from a tertiary oncology centre in Southern India Lakshmaiah Chinnagiriyappa
More informationDiagnosis and Management of Chronic Myeloid Leukaemia
Diagnosis and Management of Chronic Myeloid Leukaemia Dr Simon Watt Dr Katherine O Neill Dr Fiona Dignan Written July 2017 Prof Tim Somervaille Review July 2019 1 Table of Contents 1.0 Introduction 3 2.0
More informationStarting & stopping therapy in Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2019
Starting & stopping therapy in Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2019 Disclosures Richard A. Larson, MD Research funding to the University
More informationOutlook CML 2016: What is being done on the way to cure
New Horizons 2011 Outlook CML 2016: What is being done on the way to cure Gianantonio Rosti Dept. Of Hematology and Oncology St. Orsola-Malpighi University Hospital Bologna (Italy) GIMEMA CML Working Party
More informationCML: definition. CML epidemiology. CML diagnosis. CML: peripheralbloodsmear. Cytogenetic abnormality of CML
MolecularDiagnostic.be Third Scientific Meeting Molecular Diagnostics.be t(9;22) CML: definition Management of CML patients treated with TKI: the place of molecular monitoring Antwerp, December 13 th 11
More informationC Longer follow up on IRIS data
hronic Myeloid Leukemia Drs. Rena Buckstein, Mervat Mahrous & Eugenia Piliotis with input from Dr. J. Lipton (PMH) Updated August 2008* Updates: C Longer follow up on IRIS data Guidelines for monitoring
More informationUpdated review of nilotinib as frontline treatment for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia
For reprint orders, please contact: reprints@futuremedicine.com Updated review of nilotinib as frontline treatment for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia Nilotinib,
More informationImatinib & Ponatinib. Two ends of the spectrum in 2016s reality
Imatinib & Ponatinib Two ends of the spectrum in 2016s reality CML 2016 Benefits & risks Steve O Brien CML Horizons, May 2016 Disclosures Research funding, participation in company trial, speaker, consultant,
More informationCML TREATMENT GUIDELINES
CML TREATMENT GUIDELINES INITIAL INVESTIGATION Propose enrolment in the CML Registry of the CML-MPN Quebec Research Group. Medical history : Question for cardio-respiratory disorders, diabetes, pancreatitis,
More informationMRD in CML (BCR-ABL1)
MRD in CML (BCR-ABL1) Moleculaire Biologie en Cytometrie cursus Barbara Denys LAbo Hematologie UZ Gent 6 mei 2011 2008 Universitair Ziekenhuis Gent 1 Myeloproliferative Neoplasms o WHO classification 2008:
More informationMeasuring Response to BCR-ABL Inhibitors in Chronic Myeloid Leukemia
Review Article Measuring Response to BCR-ABL Inhibitors in Chronic Myeloid Leukemia Jerald P. Radich, MD In patients with chronic myeloid leukemia (CML), the hallmark Philadelphia chromosome is the marker
More informationCHRONIC MYELOID LEUKEMIA (CML) Managing the Long and the Short of It
CHRONIC MYELOID LEUKEMIA (CML) Managing the Long and the Short of It Jeffrey H Lipton PhD MD Princess Margaret Cancer Centre Professor of Medicine University of Toronto CAGPO Annual Conference St. John
More informationThe speaker has no financial relationships with a commercial interest to disclose and no conflicts of interest to resolve.
Hana Safah MD Professor of Medicine Tulane University School of Medicine Director of the SCT program, Tulane Medical Center The speaker has no financial relationships with a commercial interest to disclose
More informationMedical Benefit Effective Date: 07/01/12 Next Review Date: 03/13 Preauthorization* Yes Review Dates: 04/07, 05/08, 03/10, 03/11, 03/12
Hematopoietic Stem-Cell Transplantation for Chronic Myelogenous (80130) Medical Benefit Effective Date: 07/01/12 Next Review Date: 03/13 Preauthorization* Yes Review Dates: 04/07, 05/08, 03/10, 03/11,
More informationDoes Generic Imatinib Change the Treatment Approach in CML?
Does Generic Imatinib Change the Treatment Approach in CML? Jerald P. Radich, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance NCCN.org For Clinicians NCCN.org/patients For Patients
More informationDAVID S. SNYDER, M.D.
CML UPDATE 2019 DAVID S. SNYDER, M.D. MARCH 21,2019 Click to edit Master Presentation Date Disclosures I do not have anything to disclose 2001 2016 Loss in expectation of life of patients with chronic
More informationGreater Manchester and Cheshire Cancer Network Chronic Myeloid Leukaemia v3 2012
Greater Manchester and Cheshire Cancer Network Chronic Myeloid Leukaemia v3 2012 Dr Simon Watt Dr Shiva Natarajan 1.0 Introduction The landscape in chronic myeloid leukaemia (CML) has changed dramatically
More informationChronic myeloid leukemia (CML) Warunsuda Sripakdee, BCOP,BCP Prince of Songkla University
Chronic myeloid leukemia (CML) 1 Warunsuda Sripakdee, BCOP,BCP Prince of Songkla University Hematologic malignancies CML ALL AML 2 CML CD34+ results from an acquired mutation that affects hematopoietic
More informationExecutive summary Overview
Executive summary Overview In this appraisal, we have demonstrated that dasatinib is clinically more effective, as well as more cost effective, than imatinib, the current standard of care. In the pivotal
More informationMolecular pathogenesis of CML: Recent insights
Napoli 24 gennaio 2012 Molecular pathogenesis of CML: Recent insights Giuseppe Saglio University of Turin CML Biology CML Clinical practice MILESTONES IN MOLECULAR BIOLOGY OF CML 1960 - Nowell P.C. & Hungerford
More information35 Current Trends in the
35 Current Trends in the Management of Chronic Myelogenous Leukemia Abstract: CML is a hematopoietic stem cell disease which is characterized by the presence of Philadelphia chromosome (Ph-chromosome)
More informationWhat is New in Leukemia & MPN in 2011?
Leukemia Update What Did We Learn from ASCO 211? Jorge Cortes, MD Department of Leukemia MD Anderson Cancer Center Houston, Texas What is New in Leukemia & MPN in 211? Cool things happening in MPN The
More informationDati sulla sospensione della terapia
Leucemia Mieloide Cronica Dati sulla sospensione della terapia Gianantonio Rosti, Bologna BCR-ABL Loading in CML Patients 100% 10% 1% MMR MR 4 MR 4.5 STIM study design N=100 Start Imatinib CMR Sustained
More informationHull and East Yorkshire and North Lincolnshire NHS Trusts Haematology Multidisciplinary Team Guideline and Pathway. Chronic Myeloid Leukaemia
Hull and East Yorkshire and North Lincolnshire NHS Trusts Haematology Multidisciplinary Team Guideline and Pathway Chronic Myeloid Leukaemia 1 BACKGROUND The Hull and North Lincolnshire Haematology Multidisciplinary
More informationCancer Biology 2016;6(1) Imatinib Mesylate Effectiveness in Chronic Myeloid Leukemia patients in Upper Egypt. Mervat M.
Imatinib Mesylate Effectiveness in Chronic Myeloid Leukemia patients in Upper Egypt Mervat M. Omar Department of Oncology, Assuit University Hospital, Assuit, Egypt drmervatomar@yahoo.com Abstract: Background
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Bosutinib (Bosulif) for Chronic Myelogenous Leukemia April 21, 2015
pan-canadian Oncology Drug Review Final Clinical Guidance Report Bosutinib (Bosulif) for Chronic Myelogenous Leukemia April 21, 2015 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationCML UPDATE 2018 DAVID S. SNYDER, M.D. MARCH
CML UPDATE 2018 DAVID S. SNYDER, M.D. MARCH 15, 2018 Click to edit Master Presentation Date DISCLOSURES I have nothing to disclose 2001 2016 Loss in expectation of life of patients with chronic myeloid
More informationCML 301 SOME INTRODUCTION INTO CML, CML SCIENCE, DRUG DEVELOPMENT AND INFORMATION RESOURCES. by Sarunas Narbutas Jan Geissler.
CML 301 SOME INTRODUCTION INTO CML, CML SCIENCE, DRUG DEVELOPMENT AND INFORMATION RESOURCES by Sarunas Narbutas Jan Geissler 4 May 2018 CML 101 / BASICS: UNDERSTANDING THE DISCUSSIONS IN CML SESSIONS What
More informationDecision Making in CML 2010
Decision Making in CML 2010 Imatinib is the standard treatment for chronic myeloid leukaemia (CML), but approximately 25% of patients are resistant or non-responsive to imatinib. 1 While physicians have
More informationSecond-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase
Critical Reviews in Oncology/Hematology 82 (2012) 159 170 Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase Gianantonio Rosti, Fausto Castagnetti,
More informationRecent advances in the path toward the cure for chronic myeloid leukemia
VOLUME 46 ㆍ NUMBER 3 ㆍ September 2011 THE KOREAN JOURNAL OF HEMATOLOGY REVIEW ARTICLE Recent advances in the path toward the cure for chronic myeloid leukemia Dong-Wook Kim Department of Hematology, Seoul
More informationWhat Can We Expect from Imatinib? CML Case Presentation. Presenter Disclosure Information. CML Case Presentation (cont)? Session 2: 8:15 AM - 9:00 AM
Welcome to Master Class for Oncologists Session 2: 8:15 AM - 9: AM Miami, FL December 18, 29 Chronic Myelocytic Leukemia: Imatinib and Beyond Speaker: Daniel J. DeAngelo, MD, PhD Dana-Farber Cancer Institute
More informationThe Future of Chronic Myelogenous Leukemia: New Treatments on the Horizon
The Future of Chronic Myelogenous Leukemia: New Treatments on the Horizon Imatinib revolutionized the treatment of chronic myelogenous leukemia (CML), improving the prognosis to such an extent that the
More informationAGGIORNAMENTI IN EMATOLOGIA Faenza, 7 Giugno 2018 LMC: ALGORITMI TERAPEUTICI ATTUALI E IL PROBLEMA DELLA RESISTENZA.
AGGIORNAMENTI IN EMATOLOGIA Faenza, 7 Giugno 2018 LMC: ALGORITMI TERAPEUTICI ATTUALI E IL PROBLEMA DELLA RESISTENZA Michele.Baccarani@unibo.it EUROPEAN LEUKEMIANET 2013 (Blood 2013;122:885 892). RESPONSE
More informationPonatinib Withdrawal Update
Hello. This is Dr. Stuart Goldberg from the Leukemia Division at the John Theurer Cancer Center at Hackensack University Medical Center in Hackensack, New Jersey. I am speaking on behalf of ManagingCML.com
More informationPatient With Chronic Myeloid Leukemia in Complete Cytogenetic Response: What Does It Mean, and What Does One Do Next?
VOLUME 32 NUMBER 5 FEBRUARY 10 2014 JOURNAL OF CLINICAL ONCOLOGY ONCOLOGY GRAND ROUNDS Patient With Chronic Myeloid Leukemia in Complete Cytogenetic Response: What Does It Mean, and What Does One Do Next?
More informationt(9;22)(q34;q11) as part of a single or complex translocation, or BCR-ABL transcripts must be present in every case
CHRONIC MYELOID LEUKAEMIA Diagnostic Criteria Chronic phase CML t(9;22)(q34;q11) as part of a single or complex translocation, or BCR-ABL transcripts must be present in every case Maximally cellular marrow
More informationReview Article. Introduction
Review Article Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance
More informationCopyright information:
Final Analysis of the Efficacy and Safety of Omacetaxine Mepesuccinate in Patients With Chronic- or Accelerated-Phase Chronic Myeloid Leukemia: Results With 24 Months of Follow-Up Jorge Cortes, University
More informationSummary 1. Comparative effectiveness of ponatinib
Cost-effectiveness of ponatinib (Iclusig ) as indicated for adult patients with: (i) CP-, AP-, or BP- chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to
More information